| Study of Ataluren (PTC124) in Hemophilia A and B (NCT00947193) | PTC Therapeutics | 2009-10-14 |
| Study Evaluating Liver Transplantation in Haemophilia Patients in Spain (NCT00927992) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-07-01 |
| Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor (NCT00851721) | Baxalta now part of Shire | 2009-03-31 |
| Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects (NCT00866606) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-02-01 |
| Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (NCT01921855) | Bayer | 2009-01-01 |
| Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B (NCT00768287) | Medexus Pharma, Inc. | 2009-01-01 |
| Gait Evaluation in Haemophiliac Patients (NCT00824798) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2009-01-01 |
| Post Marketing Observational Study of Reformulated BeneFIX (NCT00835068) | Pfizer | 2009-01-01 |
| Phase I/IIa Study of FIXFc in Hemophilia B Patients (NCT00716716) | Bioverativ Therapeutics Inc. | 2008-04-01 |
| Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX (NCT00749476) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-04-01 |
| Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study (NCT00936312) | Weill Medical College of Cornell University | 2008-03-01 |
| Registry For Patients Treated With BeneFix In Usual Care Setting In Germany (NCT00714415) | Pfizer | 2008-01-01 |
| LTFU for Gene Transfer Subjects With Hemophilia B (NCT00515710) | Spark Therapeutics, Inc. | 2007-08-01 |
| Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B (NCT00484185) | Pfizer | 2007-08-01 |
| Study Evaluating Approach to Treatment of Haemophilia A and B in Spain (NCT00581438) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-06-01 |
| Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B (NCT00364182) | Pfizer | 2007-05-01 |
| Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients (NCT00244114) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-02-01 |
| Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B (NCT03091751) | Grifols Biologicals, LLC | 2005-08-01 |
| The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs (NCT00212459) | New York Presbyterian Hospital | 2005-05-01 |
| Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study (NCT00936845) | Weill Medical College of Cornell University | 2005-04-01 |
| Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B (NCT00195221) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-02-01 |
| Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B (NCT00076557) | Avigen | 2004-01-01 |
| Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) (NCT00139828) | Prothya Biosolutions | 2003-05-01 |
| Study Evaluating rFIX; BeneFIX in Severe Hemophilia B (NCT00037557) | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-09-01 |
| Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use (NCT00167973) | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-01-01 |
| Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B (NCT00581126) | Wyeth is now a wholly owned subsidiary of Pfizer | 2001-12-01 |
| Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency (NCT00004801) | National Center for Research Resources (NCRR) | 1992-03-01 |
| Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B (NCT00093210) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Study Evaluating rFIX; BeneFIX® in Hemophilia B (NCT00093171) | Wyeth is now a wholly owned subsidiary of Pfizer | |